<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVES: To determine the preferred treatment for patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: A questionnaire was given to <z:hpo ids='HP_0000001'>all</z:hpo> participants of the 2010 meeting of the International Society for <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's Disease </plain></SENT>
<SENT sid="2" pm="."><plain>RESULTS: Forty-one respondents from 6 different subspecialties </plain></SENT>
<SENT sid="3" pm="."><plain>In the case of a patient with (severe) <z:hpo ids='HP_0012123'>posterior uveitis</z:hpo> or parenchymal central <z:mp ids='MP_0008912'>nervous</z:mp> system (<z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>) disease no consensus was seen </plain></SENT>
<SENT sid="4" pm="."><plain>A diffuse spectrum of different schedules were given </plain></SENT>
<SENT sid="5" pm="."><plain>In both <z:hpo ids='HP_0000554'>uveitis</z:hpo> and <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease the majority of respondents preferred treatment options consisting of combination systemic therapy and systemic <z:chebi fb="0" ids="50858">corticosteroids</z:chebi> </plain></SENT>
<SENT sid="6" pm="."><plain>TNF was preferred as first line drug in <z:hpo ids='HP_0000554'>uveitis</z:hpo> in 7.5% and in severe <z:hpo ids='HP_0000554'>uveitis</z:hpo> in 32.5% of respondents </plain></SENT>
<SENT sid="7" pm="."><plain>In parenchymal <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi> disease TNF blockage was given by 17% of the respondents </plain></SENT>
<SENT sid="8" pm="."><plain>EULAR guidelines regarding <z:hpo ids='HP_0000554'>uveitis</z:hpo> were followed by 12/40 physicians </plain></SENT>
<SENT sid="9" pm="."><plain>In patients with a new <z:hpo ids='HP_0002625'>deep vein thrombosis</z:hpo>, 90% of respondents would intensify immunosuppression </plain></SENT>
<SENT sid="10" pm="."><plain>More than half would also anticoagulate </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Although consensus about how to treat patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet syndrome in different clinical situations is far from present, treatment has become more intensive when compared to 10-20 years ago </plain></SENT>
<SENT sid="12" pm="."><plain>More uniformity should be sought for in the decision process in individual patients with <z:chebi fb="6" ids="22696">Beh</z:chebi>çet's syndrome, regarding their treatment, as well as adhering to evidence, as presented in the EULAR guidelines, when present </plain></SENT>
</text></document>